Transcranial Magnetic Stimulation in Substance Use Disorder Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06066164 |
Recruitment Status :
Not yet recruiting
First Posted : October 4, 2023
Last Update Posted : October 4, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Substance Use Disorders | Device: Transcranial magnetic stimulation (TMS) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Cortical Excitability Among Substance Use Disorder Patients |
Estimated Study Start Date : | December 2023 |
Estimated Primary Completion Date : | September 1, 2024 |
Estimated Study Completion Date : | October 1, 2024 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: Control group |
Device: Transcranial magnetic stimulation (TMS)
Trans-cranial magnetic stimulation (TMS) is a safe and painless technique for evoking activity in neurons in the human brain through the intact scalp and skull To measure cortical excitability |
Active Comparator: Polysubstance use disorder patients |
Device: Transcranial magnetic stimulation (TMS)
Trans-cranial magnetic stimulation (TMS) is a safe and painless technique for evoking activity in neurons in the human brain through the intact scalp and skull To measure cortical excitability |
Active Comparator: Monosubstance use disorder patients |
Device: Transcranial magnetic stimulation (TMS)
Trans-cranial magnetic stimulation (TMS) is a safe and painless technique for evoking activity in neurons in the human brain through the intact scalp and skull To measure cortical excitability |
- Measure cortical excitability in substance use disorder patients by TMS [ Time Frame: Baseline ]Estimation of cortical excitability in substance use disorder patients and compare it in mono substance use disorder patients and poly substance use disorder patients
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age:above18yearsold
- males only
- Patients fulfilling diagnostic criteria of substance use disorder according to DSM-5
Exclusion Criteria:
- 1. patients with other comorbid psychatric disorders. 2-patients with medical disease. 3.patients wirh epilepsy or family history of epilepsy. 4-cardiac pacemaker 5-metal implants in head as participant will be applied to magnetic field of the TMS 6-age yonnger than 18
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06066164
Contact: Abdelrahman H Goda | 01061236939 | Abdelrahmangoda17@gmail.com |
Responsible Party: | Abdelrahman Goda, AbdGoda, Assiut University |
ClinicalTrials.gov Identifier: | NCT06066164 |
Other Study ID Numbers: |
Tms in SUD patients |
First Posted: | October 4, 2023 Key Record Dates |
Last Update Posted: | October 4, 2023 |
Last Verified: | September 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Substance-Related Disorders Chemically-Induced Disorders Mental Disorders |